Media Releases - 2008

	Orchid receives US FDA approval for Divalproex Sodium DR Tablets
	Orchid’s revenue during Q2FY09 rises by 18.7% to Rs 348.45 crore Achieves salient progress in the Generics and R&D verticals
	Orchid receives US FDA approvals for three Cefuroxime Inj. ANDAs
	Orchid & Merck & Co., Inc. collaborate to develop novel anti-infective drugs
	Orchid to develop Novel Anticoagulant Drug Candidate from Merck To participate in Diakron which holds the worldwide rights for the compound
	Orchid receives EU approvals for Piperacillin Tazobactam injection
	Orchid’s Q1 FY09 income grows 30%
	Orchid receives Canadian approval for Piperacillin Tazobactam injection
	Orchid’s FY08 turnover rises by 36% to Rs 1239 crore Net profit records a growth of 91%
	Ranbaxy and Orchid announce strategic business alliance To leverage respective strengths for mutually beneficial business growth
	Orchid announces the formation of its Japanese Subsidiary, Orchid Pharma Japan KK To drive foray into the growing high potential Japanese generics market
	Orchid Chemicals clarifies on market fall of its shares
	Orchid receives US FDA approval for Cefuroxime Axetil ANDA 25th ANDA approval for Orchid
	Orchid receives USFDA nod for Granisetron generic formulation First Indian company to be approved for this non-antibiotic product
	Orchid ropes in Dr Gopalan to head its Drug Discovery initiatives To head Orchid Research Labs as CSO & Director
	Orchid’s Q3 FY08 revenue up by 39% to Rs 333 crore Net profit rises by 91% to Rs 54 crore
	Orchid’s formulation facilities receive MCC (South Africa) nod Cephalosporin & Penicillin Injectable facilities approved